M
Matthew M. Gubin
Researcher at Washington University in St. Louis
Publications - 34
Citations - 7339
Matthew M. Gubin is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Immunotherapy & Immune system. The author has an hindex of 18, co-authored 24 publications receiving 5363 citations. Previous affiliations of Matthew M. Gubin include University of Texas MD Anderson Cancer Center & University of Missouri.
Papers
More filters
Journal ArticleDOI
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang,Jing Qiu,David O’Sullivan,Michael D. Buck,Takuro Noguchi,Jonathan D. Curtis,Qiongyu Chen,Mariel Gindin,Matthew M. Gubin,Gerritje J.W. van der Windt,Elena Tonc,Robert D. Schreiber,Edward J. Pearce,Erika L. Pearce +13 more
TL;DR: It is shown that tumor-imposed metabolic restrictions can mediate T cell hyporesponsiveness during cancer, and it is found that blocking PD-L1 directly on tumors dampens glycolysis by inhibiting mTOR activity and decreasing expression of gly colysis enzymes.
Journal ArticleDOI
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin,Xiuli Zhang,Heiko Schuster,Etienne Caron,Jeffrey P. Ward,Takuro Noguchi,Yulia Ivanova,Jasreet Hundal,Cora D. Arthur,Willem Jan Krebber,Gwenn E. Mulder,Mireille Toebes,Matthew D. Vesely,Samuel S. K. Lam,Alan J. Korman,James P. Allison,Gordon J. Freeman,Arlene H. Sharpe,Erika L. Pearce,Ton N. Schumacher,Ruedi Aebersold,Hans-Georg Rammensee,Cornelis J. M. Melief,Elaine R. Mardis,William E. Gillanders,Maxim N. Artyomov,Robert D. Schreiber +26 more
TL;DR: Tumour-specific mutant proteins are identified as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and it is shown that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy.
Journal ArticleDOI
New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape
TL;DR: This review focuses on important recent developments that have enhanced the understanding of each phase of the cancer immunoediting process, summarizes the discovery of new predictive and prognostic biomarkers and discusses development of novel and objectively effective cancer immunotherapies.
Journal ArticleDOI
Tumor neoantigens: building a framework for personalized cancer immunotherapy
TL;DR: The identification of mutated and aberrantly expressed self-tumor antigens has been a time consuming and laborious task as mentioned in this paper, which has been solved by using next-generation sequencing and epitope prediction.
Journal ArticleDOI
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach,Danielle M. Lussier,Alexander P. Miceli,Ilya Kizhvatov,Michel DuPage,Michel DuPage,Adrienne M. Luoma,Wei Meng,Cheryl F. Lichti,Ekaterina Esaulova,Anthony N. Vomund,Daniele Runci,Jeffrey P. Ward,Matthew M. Gubin,Ruan F.V. Medrano,Cora D. Arthur,J. Michael White,Kathleen C. F. Sheehan,Alexander Chen,Kai W. Wucherpfennig,Tyler Jacks,Emil R. Unanue,Maxim N. Artyomov,Robert D. Schreiber +23 more
TL;DR: It is shown that spontaneous and immunotherapy-induced anti-tumour responses require the activity of both tumour-antigen-specific CD8+ and CD4+ T cells, even in tumours that do not express major histocompatibility complex (MHC) class II molecules.